The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: Development of a novel therapeutic vaccine candidate  by Liu, Yuanjie et al.
07) 10–19
www.elsevier.com/locate/yviroVirology 365 (20The role of the downstream signal sequences in the maturation of the
HBV middle surface glycoprotein: Development of a novel
therapeutic vaccine candidate
Yuanjie Liu a, Ender Simsek a, Pamela Norton a, Gomathinayagam Sinnathamby b, Ramila Philip b,
Timothy Block a, Tianlun Zhou b, Anand Mehta a,⁎
a Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA 18902, USA
b Institute for Hepatitis and Virus Research, Doylestown, PA 18902, USA
Received 31 October 2006; returned to author for revision 18 December 2006; accepted 6 March 2007
Available online 25 April 2007Abstract
The signal sequences that mediate entry of the hepatitis B virus (HBV) envelope proteins into the endoplasmic reticulum (ER) are located within
the S domain at positions 11–32 and at positions 80–98 (from the start of the S domain). In addition, hydrophobic patches at positions 160–184 and
189–210 of the S domain may also be involved in entry into the ER. The role of each of these domains in the entry of the HBV M glycoprotein into
the ER was studied by deletion mutations of each of the signal sequences. Glycosylation of proteins was used as a marker of entry into the ER. Our
results indicate that association with the ER could not be prevented by the deletion of either individual or combinations of the HBV signal
sequences. M protein lacking signal sequence I was able to enter the ER and had limited secretion. In contrast, M protein lacking signal sequence II
could not be secreted but still entered the ER. M protein lacking signal sequences I and II, while still associated with the ER, was rapidly degraded
by the cytosolic proteasome. The potential use of such a vector as a CTL vaccine was tested through an in vitro antigen presentation assay. In this
assay, a DNA vaccine candidate lacking signal sequences I and II lead to a >6-fold increase in CTL activation, as compared to the vector expressing
wild type M protein. These results suggest that increased degradation of the HBV envelope proteins can lead to enhanced antigen presentation.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; Glycosylation; Secretion; Antigen presentation; VaccineIntroduction
Hepatitis B virus specifies three envelope proteins, called large
(L), middle (M), and small (S) that are all derived from the same
open reading frame (ORF) and may exist as either unglycosylated
or N-glycosylated forms (Gerlich et al., 1992). These glycopro-
teins, when entering the endoplasmic reticulum, can form large
particles that can be secreted in the absence of other viral proteins.
The entry of proteins into the endoplasmic reticulum (ER) for
post-translational modification and secretion generally requires
the use of well-defined sequences that act to initiate entry into the
ER. These are often referred to as signal sequences.Many proteins
contain N-terminal signal sequences that are removed after entry
into the ER by signal peptidases. Additionally, proteins can⁎ Corresponding author.
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doi:10.1016/j.virol.2007.03.042contain internal signal sequences that mediate entry into the ER
and are not cleaved but rather act to anchor the protein in the lipid
bilayer. The HBV envelope proteins contain 4 hydrophobic
domains that could act as transmembrane domains and signal
sequence domains. These are contained within the S domain and
are downstream of the start of both the M and L proteins. That is,
the consensus signal sequences are at positions 66–87 (Sig I) and
135–153 (Sig II) of theM protein within the S domain (Eble et al.,
1986, 1987, 1990; Lambert and Prange, 2001). This is shown in
Fig. 1. Prior work has suggested that downstream signal
sequences mediate the entry of the pre-S2 domain into the ER
in an in vitro translation system (Eble et al., 1990). To further
study the role of these signal sequences in the entry of the M
protein into the ER, we deleted each of the consensus signal
sequences and examined the ability of the M protein to enter the
ER in cells transfected with HBV DNA. Surprisingly, our results
indicate that neither the deletion of single nor multiple signal
11Y. Liu et al. / Virology 365 (2007) 10–19sequences prevented association with the ER. However, modified
HBV M protein lacking signal sequences I and II was rapidly
degraded by the cytosolic proteasome. Since rapid degradation of
proteinsmay lead to enhanced antigen presentation, we employed
an in vitro antigen presentation system to assess antigen
presentation. Our results demonstrate that antigen presentation
is indeed enhanced. The role of the HBV signal sequences and the
development of novel CTL vaccines are discussed.
Results
Deletion of individual signal sequences does not prevent entry
into the ER
To examine the requirements for the entry of the HBV M
protein into the ER, we created a series of HBV M mutants that
contained deletions within the 4 major transmembrane domains.
These are shown in Figs. 1a and b and each individual vector
shown in Fig. 1b was transfected into Hep G2 cells. The levels
of intracellular and extracellular M protein were determined by
immunoblot using an antibody to amino acids 13–26 of the Pre-
S2 domain or via ELISA using an antibody to the “a” epitope of
the S domain respectively. These results are shown in Fig. 2.
Fig. 2a shows the level of intracellular M protein after
transfection into Hep G2 cells. As indicated, with the exception
of the Δsignal I&II expression vector, all of the vectors
produced multiple forms of M reactive protein, suggesting that
glycosylation and hence entry into the ER had occurred.
Surprisingly, while the deletions of Signal sequence II, III or IV
prevented secretion of the M protein, the Δsignal I expressionFig. 1. (a) The HBV envelope proteins and the signal sequence predicted to mediate
while bottom panel shows the relative positions of the 4 major transmembrane doma
Pre-S2 (found only on the M protein) and on amino acid 146 of the S domain (Eble e
were made within all four predicted transmembrane domains within the S domain (Eb
the lack of a “–” mark.vector was still capable of secreting M protein into the culture
medium (Fig. 2b).
The entry of each of the mutant proteins into the ER was
tested by treatment with PNGase F and Endo H. PNGase F is an
amidohydrolase that cleaves the N-glycosidic linkage between
the core N-acetylglucosamine and asparagines to remove all N-
linked oligosaccharides while Endo H will only remove N-
linked glycans containing non complex type glycans (Comunale
et al., 2004; Dwek et al., 1993, 2002). AsN-linked glycosylation
occurs exclusively in the endoplasmic reticulum (ER), the
addition of an N-linked glycan would indicate entry into the ER.
Thus, each HBV M expression vector was transfected into Hep
G2 cells and the cell lysates analyzed by immunoblot using the
pre-S2 specific antibody either after mock treatment or treatment
with PNGase F or Endo H. As Fig. 3 shows, the W/T HBV M
expression vector produced multiple bands that collapsed down
to a single band after treatment with either PNGase F or Endo H.
Similarly, mutants containing deletions of signal sequences I, II,
and III and IV still resulted in polypeptides that were
glycosylated. Only when both signal I and II were deleted did
the M protein fail to become glycosylated.
HBV M protein lacking signal sequence I and II is rapidly
degraded by the cytosolic proteasomal complex
The ΔSig I&II expression vector gave rise to a single band of
lesser intensity than the other bands (when normalized to actin).
As this proteinwas not glycosylated, andmay not have entered the
ER, it was possible that this protein was being degraded by the
cytosolic proteasome complex. To test that hypothesis, weentry into the ER. Top panel shows the 3 HBV envelope proteins (L, M and S)
ins along with the location of the N-linked glycosylation sites at amino acid 4 of
t al., 1986, 1987). (b) HBVM expression vectors utilized in this study. Deletions
le et al., 1986, 1987). The S AUG was not modified. Deletions are indicated by
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Fig. 2. Intracellular expression of protein produced by the HBV M expression
vectors utilized in this study. (a) Expression vectors were transfected into Hep
G2 cells and the level of intracellular M protein detected 2 days later via
immunoblot using a pre-S2 specific antibody (aa 13–26 of pre-S2). All
expression vectors, except for the ΔSig I&II vector, lead to the production of
multiple species, implying glycosylation. The level of β-actin was used to
monitor loading and shown below the M protein immunoblot. (b) The secretion
of the proteins produced by the mutant expression vectors. Expression vectors
described in Figs. 1 and 2 were transfected into Hep G2 cells and the level of
HBV M protein detected in the culture medium by ELISA using an antibody to
the “a” epitope within the S domain (Abbott ELISA). Similar results were
obtained via immunoblot with pre-S2 specific antibody.
Fig. 3. (a) The deletion of signal sequence I or II does not prevent entry into the
ER. The W/T, ΔSig I, and ΔSig II expression vectors all produced multiple
species when transfected into Hep G2 cells. To test if the multiple species were
the results of glycosylation, samples were treated with the endoglycosidases
PNGase F (P) and Endo H (E). The wild type M protein contained two bands
(presumed to be gp36 and gp33) that collapsed to a single unglycosylated band
at p30. With the ΔSig I and ΔSig II expression vectors a single glycosylated
species was present that collapsed to a single unglycosylated band following
treatment. Levels of β-actin were used to control for protein loading. (b)
Deletion of both Signal sequence I and II prevents glycosylation. The sensitivity
of the multiple species of M protein seen with the ΔSig I&II, and ΔSig III&IV
expression vectors was tested via treatment with the endoglycosidases PNGase F
(P) and Endo H (E). While both the W/T and ΔSig III&IV expression vectors
presented two glycosylated species, the ΔSig I&II expression vector produces
only an unglycosylated band. As the ΔSig I&II mutant was unstable, samples
utilized for this figure were from epoxomicin treated cells (same samples used in
Fig. 5). The level of β-actin was used to monitor loading and shown below the
M protein immunoblot.
Fig. 4. Expression vectors lacking signal sequences I and II produce
unglycosylated M protein that is rapidly degraded via the cytosolic proteasome
complex. The W/T, ΔSig I, ΔSig II or ΔSig I&II expression vectors were
transfected in Hep G2 cells and either left untreated (−) or treated with the
proteasome inhibitor epoxomicin (+) for 16 h. The location of the three major
M protein species are indicated. The accumulation of the M protein from the
ΔSig I&II expression vector in the presence of the proteasome inhibitor
implies that this protein is being degraded in a proteasome dependent manner.
The level of β-actin was used to monitor loading and shown below the M
protein immunoblot.
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expression vectors in Hep G2 cells either in the absence or
presence of the proteasomal inhibitor epoxomicin. Epoxomicin is
specific for the proteasome and does not inhibit nonproteasomal
proteases such as trypsin, chymotrypsin, papain, cathepsin B,
calpain, or tripeptidyl peptidase II (Schwarz et al., 2000).As Fig. 4
shows, a small portion of theM protein appears to be degraded by
the cytosolic proteasome, as a slight accumulation of M protein is
seen when the inhibitor is present. This is true as well for the
Δsignal I and Δsignal II expression vectors where only a small
accumulation is seen with the overnight incubation with the
proteasome inhibitor. In contrast, treatment of cells transfected
with theΔsignal I&II expression vector with epoxomicin leads to
the dramatic increase in the level of M protein within the cell,
indicating that this mutant protein is being degraded by the
cytosolic proteasomal complex. Similar results were obtained
with other inhibitors of the proteasome such as lactacystin and
MG-132 (data not shown).
Subcellular localization of HBV M protein lacking signal
sequence I and II
Based upon the results presented in Figs. 2–4, it appears that
only the deletion of both signal sequence I and II prevents entryinto the ER, as proteins produced by all other expression vectors
become glycosylated. Three possible models could predict the
lack of glycosylation of the signal I and II vector and are
presented in Fig. 5a. In the first model (model A), the mutant M
protein would be located primarily in the cytosol with no
interaction with the ER. In the second model (model B), the
mutant M protein would be associated with the ER with entry of
14 Y. Liu et al. / Virology 365 (2007) 10–19the pre-S2 domain into the ER. In the last model (model C), the
mutant M protein would be associated with the ER but the pre-
S2 domain would be cytosolic. To test these models, we
analyzed purified microsomes from cells transfected with either
the W/T expression vector or the Δsignal I&II expression
vector. In both cases, cells were examined in the absence or
presence of the proteasome inhibitor, epoxomicin. The top
panel of Fig. 5b shows an immunoblot for the ER resident
protein, calnexin, in the soluble and pellet fractions after
fractionation. As this panel shows, calnexin is only associated
with the pellet (microsome) fraction. The location of the W/T
and Δsignal I&II M protein is shown on the bottom panel in
Fig. 5b. As Fig. 5b shows, in the absence of the proteasome
inhibitor, the W/T expression vector produces three bands
(unglycosylated, singly glycosylated, and doubly glycosylated
isoforms) that are associated with the ER, as they co-localize
with the ER resident protein calnexin. A small amount of singly
and doubly glycosylated bands can be seen in the soluble
fraction, suggesting that these have formed a particle and have
budded into the lumen of the ER (Werr and Prange, 1998).
Treatment with epoxomicin also did not change the relative
abundance of the three W/TM protein bands associated with the
pellet fraction. However, a slight increase in the p30 M species
was seen in the soluble fraction, suggesting that this was being
sent to the proteasome for degradation. Surprisingly, the ΔSig
I&II expression vector, which only produced unglycosylated M
protein, was associated solely with the pellet fraction, suggest-
ing that M protein lacking signal sequence I and II was still able
to interact with the ER. This would indicate that model A is not
the correct model of the ΔSig I&II mutant.
To test model B (see Fig. 5a), the microsomal fraction was
digested with trypsin for 1 h either in the absence or in the
presence of detergent to disrupt the microsomes (Bruss et al.,
1994; Lambert and Prange, 2001; Prange and Streeck, 1995).
Complete digestion of the M protein with trypsin produces 9
fragments ranging from 708 to 6841 Da. However, when the
HBVenvelope proteins are contained within a microsome, they
are protected from complete digestion (Lambert and Prange,
2001; Prange and Streeck, 1995). Thus, as expected, the W/T M
protein was only partially sensitive to trypsin digestion when
the protease was incubated with just microsomes. Interestingly,
as Fig. 5c shows, the wild type p30 isoform appeared to be more
sensitive to trypsin digestion, suggesting that its conformation
may be different than the glycosylated forms of M. Treatment ofFig. 5. (a) Three possible models of theΔSignal I&II protein. Left panel shows the re
the N-linked glycosylation sites at amino acid 4 of Pre-S2 and on amino acid 146 of th
primarily in the cytosol with no interaction with the ER. In the second model (model B
domain into the ER. In the last model (model C), the mutant M protein would be asso
of the M protein with microsomes. To test if the deletion of both signal sequence I an
with either the W/T expression vector or the ΔSig I&II expression vector. As deletion
experiment was performed with and without epoxomicin. ER membranes were ident
(microsome) and S is soluble fraction. (c) M protein lacking Sig I and II is sensitive
mutant was still associated with the microsomal fraction, we tested its sensitivity to try
the W/T expression vector that shows partial sensitivity in the absence of detergent a
fully degraded via trypsin treatment both with and without detergent present. The bott
to the results with the wild type vector, the pre-S2 domain of the ΔSig II mutant is
Digestion of microsomes with NP-40 leads to exposure and degradation of the p
investigation.microsomes with NP-40 lead to complete digestion of the M
protein, consistent with the hypothesis that the membranes had
been disrupted and the M protein was fully available to the
trypsin. In contrast, the pre-S2 epitope was lost when the ΔSig
I&II mutant was digested with trypsin regardless of whether
detergent was present or not. This suggests that the pre-S2
domain of the ΔSig I&II mutant is not within ER and indicates
that model C (see Fig. 5a) is the correct model of the ΔSig I&II
mutant. When similar experiments were performed with the
ΔSig II mutant, the pre-S2 domain was protected, suggesting
that signal sequence I could mediate entry of the pre-S2 domain
into the ER (bottom panel of Fig. 5c). Similar to the results with
the wild type expression vector, disruption of the microsome
with detergent resulted in the disappearance of the upper
glycosylated band following trypsin digestion. Interestingly, the
p30 band from the ΔSig II mutant was resistant to trypsin, even
when microsomes were incubated with detergent.
Potential use of the ΔSig I&II mutant as a CTL DNA vaccine
vector
As the Δsignal I&II expression vector was rapidly degraded
in the cell in a proteasome-dependent manner, it was hypo-
thesized that the greater degradation of this protein might
potentially lead to greater antigen presentation via the MHC
class I pathway. To test this hypothesis, the wild type and
Δsignal I&II expression vectors were engineered to contain the
H-2Kb-restricted OVA257-264 SIINFEKL epitope at the N-
terminus of the M protein (shown in Fig. 6a) (Golovina et al.,
2005; Karttunen et al., 1992; Karttunen and Shastri, 1991). The
relative stability of these vectors was compared to the non-
tagged variant by Western blotting following transfection into
Hep G2 cells as described before. As Fig. 6b shows, consistent
with the results shown in Fig. 4, a similar amount of M protein is
seen when cells are either left untreated or treated with the
proteasome inhibitor epoxomicin. Likewise, examination of the
W/T M-Ova construct showed only slight accumulation of the
unglycosylated species following treatment of cells with
epoxomicin. Treatment with epoxomicin caused significant
accumulation of both the ΔSig I&II M protein and the ΔSig
I&II-Ova M protein (shown in Fig. 6b).
These vectors were transfected into mouse L-Kb cells and the
level of antigen presentation was determined using a CTL clone
(B3.Z) for the SIINFEKL epitope (Karttunen et al., 1992;lative positions of the 4 major transmembrane domains along with the location of
e S domain. In the first model (model A), the mutant M protein would be located
), the mutant M protein would be associated with the ER with entry of the pre-S2
ciated with the ER but the pre-S2 domain would be cytosolic. (b) The association
d II prevented entry into the ER, we isolated microsomes from cells transfected
of signal sequence I and II resulted in rapid degradation via the proteasome, the
ified using an antibody to calnexin, an ER resident chaperone protein. P is pellet
to protease digestion in the absence of detergents. As the Sig I and II deletion
psin in the presence or absence of detergent. On the left panel are the results with
nd full sensitivity when detergent is present. In contrast, the ΔSig I&II mutant is
om panel shows the sensitivity of theΔSig II mutant to trypsin digestion. Similar
resistant to digestion with trypsin, suggesting entry into the lumen of the ER.
re-S2 domain. The p30 band is resistant in all cases. This is currently under
15Y. Liu et al. / Virology 365 (2007) 10–19Karttunen and Shastri, 1991). When activated through interac-
tion with a target cell presenting the SIINFEKL epitope in the
context of a H-2Kb class I molecule, the B3.Z clone will activate
a β-galactosidase gene allowing for easy monitoring of CTL
recognition and activation. The level of β-galactosidase can be
measured using a commercially available chemiluminescentsubstrate. As Fig. 6c shows, transfection of neither the W/T nor
ΔSig I&II expression vectors can activate the B3.Z CTL clone
and hence have background levels of luminescence, similar to
mock transfected L-Kb cells. In contrast both the W/T M-Ova
and theΔSig I&II-Ova M constructs lead to the activation of the
B3.Z clone, as both of these vectors lead to the activation of the
16 Y. Liu et al. / Virology 365 (2007) 10–19β-galactosidase gene. However, there was a clear, statistical
difference (P<0.001) in the level of activation observed with
the W/T M-Ova and the ΔSig I&II-Ova M constructs. That is,
as shown in Fig. 6c, the ΔSig I&II-Ova M constructs lead to a
mean 6.3-fold increase in the level of CTL activation as
compared to the W/T M-Ova construct.
Discussion
The entry of proteins into the endoplasmic reticulum (ER) for
post-translational modification and secretion generally requires
the use of well-defined sequences that act to initiate entry into the
ER. These are often referred to as signal sequences. Many
proteins contain N-terminal signal sequences that are removed
after entry into the ER by signal peptidases. Additionally, pro-
teins can contain internal signal sequences that mediate entry
into the ER and are not cleaved but rather act to anchor the
protein in the lipid bilayer. The HBVenvelope proteins contain 4
hydrophobic domains that could act as transmembrane domains
and signal sequence domains. These are contained within the S
domain and hence are downstream of the start of both the M and
L proteins. Prior work has shown that signal sequence I could
mediate the entry of a downstream sequence into the ER (Eble et
al., 1987, 1990). The work here does not conflict with this result
but rather indicates that while signal sequence Imay be sufficient
to mediate entry, it is not necessary, since we show that the HBV
M protein can utilize other transmembrane domains to enter the
ER and mediate secretion. Consistent with our results, the
deletion of signal sequence I does not prevent the ER association
of the HBV L protein (Lambert and Prange, 2001). Indeed, the
removal of signal sequence I did not prevent entry into the ER
and only lead to a 50% reduction in particle secretion. While the
removal of signal sequence II also did not fully prevent
association with the ER, it did prevent secretion, as did all
other deletions (see Fig. 1b).
Quite surprisingly, the removal of both signal sequence I and
II, while preventing the glycosylation of the molecule, did not
prevent association with the ER. Based upon the lack of
glycosylation of the S domain, and the sensitivity of the pre-S2
domain to trypsin, it was determined that the association of the
ER occurred through the hydrophobic sequences at positions
160–184 and 189–209 of the S domain. However, this protein
was highly unstable and rapidly degraded in a proteasome-
dependent manner (see Fig. 4). The mechanism of degradation
may be the result of ubiquitination of cytosolic lysine residues
that would normally be on the cytosolic side of the ER, as shown
in model C of Fig. 5a. This is currently under examination.
The rapid rate of degradation presents a therapeutic oppor-
tunity, as the unstable protein was quickly degraded via the
cytosolic proteasome. Indeed, using an epitope tagged expres-
sion vector, cells transfected with expression vectors lacking
signal sequence I and II activated specific CTLs 6.3 times
greater than the wild type expression vector. This result implies
that the enhanced degradation of the HBV envelope proteins
may lead to increased antigen presentation (Golovina et al.,
2005). These results also suggest that peptides generated by
DRiP (defective ribosome initiation products) are not saturatingfor the HBV M protein and that further antigen presentation
could be obtained via agents that could potentially cause the
proteasomal degradation of the HBVenvelope proteins (Simsek
et al., 2005).
It is noted that in our previous work examining the role of
N-linked glycan processing, we have discovered that under
normal conditions, very little of the HBV M and L protein
undergoes degradation through the proteasome pathway (Sim-
sek et al., 2005). In contrast, inhibition of the ER α-glucosidases
causes the rapid degradation of both glycosylated and
unglycosylated M and L protein in a proteasome-dependent
manner (Simsek et al., 2005). This was somewhat surprising,
since even under constitutive conditions of M and L synthesis,
some misfolding would be expected to occur, and an amount of
proteasomal degradation would be expected.
One possibility was that the formation of large viral lipo-
protein particles immediately after synthesis of the individual
HBV envelope proteins, renders them unsuitable for the
endoplasmic reticulum-associated degradation (ERAD) path-
way (Block et al., 2006). That is, as ERAD involves the retro-
translocation out of the ER through the translocon pore, which
is only 10–80 Å, the movement of a 22-nm particle out of the
ER may prove problematic. In this case, since proteasomal
degradation is a source of peptides for MHC class I loading, the
entry of these proteins into the ER and the rapid multimer
formation of HBsAgs would be a mechanism of immune
evasion.
Materials and methods
Cells and compounds
Hep G2 cells, a stable tissue culture line derived from a
human hepatoblastoma, were purchased from the American
Type Culture Collection (Rockville, MD), and grown in RPMI
1640 (Gibco-BRL, Rockville, MD) containing 10% fetal bovine
serum (Gibco-BRL). L-Kb cells (L929 transfected with H-2Kb
class I molecule) were maintained in DMEM with 5% FBS and
the T cell hybridomas (B3.Z) were maintained in RPMI 1640
supplemented with 10% FBS, 0.05 mM 2-ME, and 1 mM
sodium pyruvate. Proteasome inhibitors (lactacystin and epoxo-
micin) were purchased from Sigma (St. Louis, MO) and
Calbiochem Inc. (La Jolla, CA), respectively.
Construction of plasmids
The HBV middle and small surface protein sequences
(nt-3174-1-1980) were derived from ayw subtype (VO1460)
through pfu PCR (Stratagene, La Jolla, CA) amplification and
cloned into pCMV-Tag4A (Stratagene) plasmids by the removal
of FLAG and SV40 poly A sequences from the backbone,
referred as pCMV-MS. Since a leader sequence from human
hemoglobin gene exon1 was added in front of the HBV surface
protein open reading frame, the 2.1-kb mRNA preferentially
supports the translation of HBV middle protein. Six signal
sequence deletion mutants of HBV M protein were made via
joint PCR method and were sequenced for coding fidelity, and
Fig. 6. (a) HBVW/TM-Ova and theΔSig I&II-Ova M expression vectors utilized in this study. The wild type andΔsignal I&II expression vectors were engineered to
contain the H-2Kb-restricted OVA257-264 SIINFEKL epitope at the N-terminus of the M protein. Deletions are indicated by the lack of a “–”mark. (b) Expression of
theW/TM-Ova andΔSig I&II-OvaM vectors byWestern Blot. TheW/TM,ΔSig I&II M,W/TM-Ova and the expression vectors were transfected in Hep G2 cells as
in Fig. 4, and either left untreated (−) or treated with the proteasome inhibitor epoxomicin (+) overnight. Treatment with epoxomicin caused slight accumulation of the
unglycosylated species of W/T M-Ova construct and significant accumulation of both the ΔSig I&II-Ova M protein following treatment with epoxomicin. (c) In vitro
antigen presentation assay shows theΔSig I&II-Ova M construct enhances the level of CTL activation, as compared to the W/T M-Ova construct. Neither transfection
of the W/T norΔSig I&II expression vectors can activate the B3.Z CTL clone and hence they produce background levels of luminescence, similar to mock transfected
L-Kb cells. In contrast both the W/T M-Ova and the ΔSig I&II-Ova M construct lead to the activation of the B3.Z clone. However, the ΔSig I&II-Ova M constructs
lead to a mean 6.3-fold increase in the level of CTL activation, as compared to the W/T M-Ova construct.
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18 Y. Liu et al. / Virology 365 (2007) 10–19are called Δsignal I, Δsignal II, Δsignal I&II, Δsignal III,
Δsignal IV, Δsignal III&IV. W/T M-Ova and the ΔSig I&II-
Ova were generated by placing the H-2Kb-restricted OVA 257–
264 SIINFEKL epitope at the N-terminus of the M protein.
Plasmids and transfection
Hep G2 cells and L-Kb cells were transfected with the wild
type and mutant pCMV-M expression vectors using FuGene 6
(Roche, Indianapolis, IN) and Lipofectamine (Invitrogen, Carls-
bad, CA) respectively, according to manufacturer's directions. As
a control, pCMV-GFP was used to monitor transfection
efficiency. After transfection, the cells were allowed 1 day for
recovery then treated with epoxomicin for overnight. Next, the
cells were harvested in cell lysis buffer containing 1× protease
inhibitors and the M proteins detected byWestern blot (Simsek et
al., 2005) or Abbott ELISA (Abbott Diagnostics, Chicago, IL).
Detection of hepatitis B middle (M) surface antigens by
Western blot
HBV middle glycoproteins, from lysed cells, were dissolved
in loading buffer, resolved by electrophoresis through 12% SDS/
polyacrylamide gels (SDS/PAGE), transferred to polyvinylidene
difluoride (Millipore, Cambridge MA) membranes, and blocked
with 5% powdered milk in 0.1% Tween-20–PBS at room
temperature for 1 h. After incubation with polyclonal pre-S2
antibody (Research Diagnostics, Inc., Concord MA) at a 1 to
1000 dilution in 0.1% Tween-20 with 2% BSA for 2 h at room
temperature, the blot was washed three times with 0.1% Tween-
20–PBS for 10 min/each wash. The blot was incubated with
secondary antibody (peroxidase-conjugated donkey anti-rabbit
IgG serum) at a 1 to 5000 dilution in 0.1% Tween-20 with 2%
BSA for 1 h at room temperature. Blots werewashed 3 timeswith
0.1% Tween-20–PBS and detected by enhanced chemilumines-
cence (ECL; Amersham corporation, Arlington Heights, IL).
Detection of hepatitis B surface antigen by ELISA
About 200 μl of media from the same studies was used to
determine the level of hepatitis B surface antigen (HBsAg) in
the culture medium of untreated and treated cells. Analysis was
performed using the Abbott Diagnostics AUSZYME Mono-
clonal Diagnostic kit according to manufacturer's directions
(Abbott Laboratories, North Chicago, IL).
Microsomal fractionation
Hep G2 cells were transfected either with the W/T M, ΔSig
I&II, orΔSig II. After the cells were collected, they were washed
with cold TBS (50 mM Tris–HCl, pH 7.5, 150 mM NaCl) once.
Then, the cells were washed with hypotonic lysis buffer (20 mM
Tris pH 7.5, 5 mM MgCl2, 5 mM CaCl2, 1 mM EDTA) and
collected in 2 ml hypotonic buffer with incubation on ice for
30 min. The swollen cells were disrupted by Dounce
homogenization (40 strokes). Unbroken cells and nuclei were
removed by centrifugation for 20 min at 3000 rpm. The super-natant was layered on 3 ml 250 mM sucrose/TBS and centrifuged
at 37,000 rpm for 3 h at 4 °C in a SW55 rotor (Beckman). The
supernatant was subjected to acetone precipitation (2 volumes of
acetone, incubated at −20 °C overnight) for the detection of
cytosolic proteins. The microsomal pellet was briefly washed
with cold TBS and then carefully resuspended in 300 μl TBS for
SDS–PAGE or trypsin protection assay (Prange and Streeck,
1995). Microsomal fractions were tested for the presence of the
ER resident protein calnexin (Santa Cruz Biochemicals, Santa
Cruz, CA) by Western blot as previously described.
Trypsin protection assay
The microsomes were divided into three equal aliquots.
Trypsin (Promega, Madison, WI) was either omitted or added to
a final concentration of 25 μg/ml in the absence or the presence
of 0.5%NP-40. After a 10-min incubation at 37 °C, the reactions
were transferred to ice for 50 min. The reactions were terminated
by adding 1 μl protease inhibitor (Sigma) on ice for an additional
10 min. SDS–PAGE and Western blot were then performed for
the detection of proteins.
Antigen presentation assay
The L-Kb cells were cultured in a 24-well plate. The W/T M,
ΔSig I&II M, W/T M-Ova and the ΔSig I&II-Ova M vectors
were transfected into mouse L-Kb cells using with Lipofecta-
mine transfection reagent (Invitrogen) according to the
manufacturer's directions. After 1 day, the T cell hybridomas
(B3.Z) were added and incubated for overnight (Wherry et al.,
1999). The cells were collected and lysed in 100 μl cell lysis
solution containing 1× protease inhibitors. 5 μl cell lysates were
used for a chemiluminescent reporter assay to measure the level
of β-galactosidase produced by the B3.Z clone. The β-
galactosidase gene allows for easy monitoring of CTL
recognition and activation and the Galacto-Light Plus pur-
chased from Tropix (Bedford, MA).
Acknowledgments
Preparation of the manuscript and the work described herein
was supported by a grant from the National Institutes of Health
(AI054763), the Hepatitis B Foundation of America and The
Commonwealth of Pennsylvania. Anand Mehta is the Bruce
Witte scholar of the Hepatitis B Foundation. Ms. Lucy
Rodemich is thanked for her careful reading of the manuscript.References
Block, T.M., Mehta, A.S., Blumberg, B.S., Dwek, R.A., 2006. Does rapid
oligomerization of hepatitis B envelope proteins play a role in resistance to
proteasome degradation and enhance chronicity? DNA Cell Biol. 25 (3),
165–170.
Bruss, V., Lu, X., Thomssen, R., Gerlich, W.H., 1994. Post-translational
alterations in transmembrane topology of the hepatitis B virus large envelope
protein. EMBO J. 13 (10), 2273–2279.
Comunale, M.A., Mattu, T.S., Lowman, M.A., Evans, A.A., London, W.T.,
Semmes, O.J., Ward, M., Drake, R., Romano, P.R., Steel, L.F., Block, T.M.,
19Y. Liu et al. / Virology 365 (2007) 10–19Mehta, A., 2004. Comparative proteomic analysis of de-N-glycosylated
serum from hepatitis B carriers reveals polypeptides that correlate with
disease status. Proteomics 4 (3), 826–838.
Dwek, R.A., Edge, C.J., Harvey, D.J., Wormald, M.R., Parekh, R.B., 1993.
Analysis of glycoprotein-associated oligosaccharides. Annu. Rev. Biochem.
62 (4), 65–100.
Dwek, R.A., Butters, T.D., Platt, F.M., Zitzmann, N., 2002. Targeting
glycosylation as a therapeutic approach.Nat. Rev., DrugDiscov. 1 (1), 65–75.
Eble, B.E., Lingappa, V.R., Ganem, D., 1986. Hepatitis B surface antigen: an
unusual secreted protein initially synthesized as a transmembrane polypep-
tide. Mol. Cell. Biol. 6 (5), 1454–1463.
Eble, B.E., MacRae, D.R., Lingappa, V.R., Ganem, D., 1987. Multiple
topogenic sequences determine the transmembrane orientation of the
hepatitis B surface antigen. Mol. Cell. Biol. 7 (10), 3591–3601.
Eble, B.E., Lingappa, V.R., Ganem, D., 1990. The N-terminal (pre-S2) domain
of a hepatitis B virus surface glycoprotein is translocated across membranes
by downstream signal sequences. J. Virol. 64 (3), 1414–1419.
Gerlich, W.H., Heermann, K.H., Lu, X., 1992. Functions of hepatitis B surface
proteins. Arch. Virol., Suppl. 4, 129–132.
Golovina, T.N., Morrison, S.E., Eisenlohr, L.C., 2005. The impact of misfolding
versus targeted degradation on the efficiency of the MHC class I-restricted
antigen processing. J. Immunol. 174 (5), 2763–2769.
Karttunen, J., Shastri, N., 1991. Measurement of ligand-induced activation in
single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci.
U.S.A. 88 (9), 3972–3976.Karttunen, J., Sanderson, S., Shastri, N., 1992. Detection of rare antigen-
presenting cells by the lacZ T-cell activation assay suggests an expression
cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. U.S.A. 89 (13),
6020–6024.
Lambert, C., Prange, R., 2001. Dual topology of the hepatitis B virus large
envelope protein: determinants influencing post-translational pre-S translo-
cation. J. Biol. Chem. 276 (25), 22265–22272.
Prange, R., Streeck, R.E., 1995. Novel transmembrane topology of the hepatitis
B virus envelope proteins. EMBO J. 14 (2), 247–256.
Schwarz, K., de Giuli, R., Schmidtke, G., Kostka, S., van den Broek, M., Kim,
K.B., Crews, C.M., Kraft, R., Groettrup, M., 2000. The selective proteasome
inhibitors lactacystin and epoxomicin can be used to either up- or down-
regulate antigen presentation at nontoxic doses. J. Immunol. 164 (12),
6147–6157.
Simsek, E., Mehta, A., Zhou, T., Dwek, R.A., Block, T., 2005. Hepatitis B virus
large and middle glycoproteins are degraded by a proteasome pathway in
glucosidase-inhibited cells but not in cells with functional glucosidase
enzyme. J. Virol. 79 (20), 12914–12920.
Werr, M., Prange, R., 1998. Role for calnexin and N-linked glycosylation in the
assembly and secretion of hepatitis B virus middle envelope protein
particles. J. Virol. 72 (1), 778–782.
Wherry, E.J., McElhaugh, M.J., Eisenlohr, L.C., 1999. The induction of virus-
specific CTL as a function of increasing epitope expression: responses rise
steadily until excessively high levels of epitope are attained. J. Immunol. 163
(7), 3735–3745.
